Aberdeen Group
LXEO icon

Aberdeen Group’s Lexeo Therapeutics LXEO Stock Holding History

Aberdeen Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.14M Buy
675,092
+429,188
+175% +$2.32M ﹤0.01% 739
2026
Q1 		$1.41M Buy
+245,904
New +$1.74M ﹤0.01% 791

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Aberdeen Group's LXEO Position: Q2 2026 in Review

Aberdeen Group increased its Lexeo Therapeutics (LXEO) stake by 175% in Q2 2026, buying an estimated $2.32M and bringing the position to 675,092 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #739.

Aberdeen Group first reported a position in LXEO in Q1 2026 and has held it in 2 quarters since. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Aberdeen Group held 675,092 shares of Lexeo Therapeutics worth $3.14M as of Q2 2026.
  • Aberdeen Group bought 429,188 Lexeo Therapeutics shares in Q2 2026, an estimated $2.32M.
  • Lexeo Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #739 holding.
  • Aberdeen Group first reported a position in Lexeo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.